Monday, November 16, 2026
HomeHealthcarePharmaMankind Pharma secures India rights for Betta Pharmaceuticals' Ensartinib

Mankind Pharma secures India rights for Betta Pharmaceuticals’ Ensartinib

New Delhi, November 16, 2026: Mankind Pharma has entered into an in-licensing agreement with Betta Pharmaceuticals to obtain exclusive rights for the development, manufacturing, registration and commercialisation of Ensartinib in India, the company announced.

Ensartinib is a patented oncology drug approved by both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). The therapy is indicated for adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

Agreement expands oncology portfolio

Through this partnership, Mankind Pharma aims to strengthen its oncology portfolio and expand its presence in specialised therapies by collaborating with global pharmaceutical innovators. The company will hold exclusive rights to develop and commercialise Ensartinib in the Indian market.

Drug approved by US FDA and China’s NMPA

Ensartinib’s approval by major regulatory bodies such as the US FDA and China’s NMPA positions it as a targeted therapy option for a specific subset of lung cancer patients in India.

Mankind Pharma is a pharmaceutical company headquartered in India, with a focus on expanding its range of specialised therapies through strategic partnerships.


Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.

Ravindra Soni
Ravindra Sonihttps://businessfortnight.com
Senior journalist with 38 years of experience in print and digital media. Former Executive Editor. Founder and Editor of BusinessFortnight, covering business, economy, and policy news from Madhya Pradesh and across India.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments